Advancing Therapeutic Innovation
AI-driven discovery, laboratory validation and development expertise, brought to programs we co-develop with originating partners - from target to clinic, and toward commercialization.
Pipeline
Programs in development
Stage progress is as reported by the originating partner. Open a row for its status.
PGN-001NeurodegenerationAlzheimer's DiseaseSmall moleculeTarget/MoA: UndisclosedCurrent stage: Lead OptimizationCurrent stage: Lead OptimizationHigh priority
A small-molecule program in Alzheimer's disease that the originating partner reports has completed target discovery, with hit discovery and lead optimization activities under way.
- Lead compound
- Lead series status is held by the originating partner and is available to qualified parties under a confidentiality agreement.
- Intellectual property
- Intellectual property rests with the originating partner. Any rights for Prognica Labs or third parties will be set out in the definitive agreement.
Stage status
- Target DiscoveryCompleted
- Hit DiscoveryIn progress
- Lead OptimizationIn progress
- Preclinical DevelopmentPlanned
- Clinical DevelopmentPlanned
PGN-002Dermatology / ImmunologyVitiligoSmall moleculeTarget/MoA: UndisclosedCurrent stage: Hit DiscoveryCurrent stage: Hit DiscoveryPriority
A small-molecule program in vitiligo that the originating partner reports has completed target discovery and entered hit discovery.
- Lead compound
- Hit-finding is reported to be in progress; no lead compound has been disclosed.
- Intellectual property
- Intellectual property rests with the originating partner. Any rights for Prognica Labs or third parties will be set out in the definitive agreement.
Stage status
- Target DiscoveryCompleted
- Hit DiscoveryIn progress
- Lead OptimizationPlanned
- Preclinical DevelopmentPlanned
- Clinical DevelopmentPlanned
PGN-003OncologySolid tumorsSmall moleculeTarget/MoA: UndisclosedCurrent stage: Lead OptimizationCurrent stage: Lead OptimizationEmerging
A small-molecule oncology program in solid tumors that the originating partner reports has completed target discovery, with hit discovery and lead optimization activities under way.
- Lead compound
- Lead series status is held by the originating partner and is available to qualified parties under a confidentiality agreement.
- Intellectual property
- Intellectual property rests with the originating partner. Any rights for Prognica Labs or third parties will be set out in the definitive agreement.
Stage status
- Target DiscoveryCompleted
- Hit DiscoveryIn progress
- Lead OptimizationIn progress
- Preclinical DevelopmentPlanned
- Clinical DevelopmentPlanned
PGN-004Metabolic diseaseDiabetes / metabolic dysfunctionSmall moleculeTarget/MoA: UndisclosedCurrent stage: Target DiscoveryCurrent stage: Target DiscoveryExploratory
An exploratory small-molecule program in diabetes and metabolic dysfunction; the originating partner reports target discovery as complete.
- Lead compound
- No hit or lead compound has been disclosed.
- Intellectual property
- Intellectual property rests with the originating partner. Any rights for Prognica Labs or third parties will be set out in the definitive agreement.
Stage status
- Target DiscoveryCompleted
- Hit DiscoveryPlanned
- Lead OptimizationPlanned
- Preclinical DevelopmentPlanned
- Clinical DevelopmentPlanned
PGN-005NeurodegenerationParkinson's DiseaseSmall moleculeTarget/MoA: UndisclosedCurrent stage: Target DiscoveryCurrent stage: Target DiscoveryEarly stage
An early-stage small-molecule program in Parkinson's disease; the originating partner reports target discovery as complete.
- Lead compound
- No hit or lead compound has been disclosed.
- Intellectual property
- Intellectual property rests with the originating partner. Any rights for Prognica Labs or third parties will be set out in the definitive agreement.
Stage status
- Target DiscoveryCompleted
- Hit DiscoveryPlanned
- Lead OptimizationPlanned
- Preclinical DevelopmentPlanned
- Clinical DevelopmentPlanned
No program matches these filters.
- Completed
- In progress
- Planned
Pipeline last updated 2026-10-21
Co-development
What Prognica brings to a partnered program
The originating partner brings the science and the asset. We bring an integrated discovery-to-development engine around it - so the program moves forward without assembling five vendors.
Enterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.